Hepatitis B — Comprehensive Nursing Guide
Transmission & Risk
- Blood-borne: Needlestick, sharing needles (IVDU), transfusions
- Sexual: Unprotected sex (most common adult route in GCC)
- Vertical (perinatal): Mother to infant at birth
Perinatal Transmission Risk: If mother is HBeAg-positive, infant has 90% risk of developing chronic HBV without prophylaxis. Birth-dose vaccine + HBIG within 12 hours is essential.
Natural History
Acute (0–6 months)
Symptoms or asymptomatic; 95% of adults recover spontaneously
Chronic (>6 months HBsAg+)
5% of adults, 90% of infants infected perinatally
Cirrhosis
20–30% of untreated chronic HBV over 20–30 years
HCC
HBV is leading cause of hepatocellular carcinoma globally; 6-monthly surveillance needed
Phases of Chronic HBV Infection
| Phase | HBeAg | HBV DNA | ALT | Significance |
|---|
| Immune Tolerant | + | Very High | Normal | Common in perinatally infected; low fibrosis |
| Immune Active (HBeAg+) | + | High | Elevated | Active hepatitis; treat if sustained elevation |
| Immune Control (Inactive carrier) | − | Low/undetectable | Normal | HBeAg seroconversion; low risk |
| HBeAg-negative Active | − | Moderate | Elevated | Pre-core mutant; treat |
| Reactivation | Variable | Rising | Elevated | During immunosuppression; prophylax |
HBV Serology Interpretation
| HBsAg | Anti-HBs | Anti-HBc Total | IgM Anti-HBc | HBeAg | Interpretation |
|---|
| − | − | − | − | − | Susceptible — never infected, not vaccinated |
| − | + | − | − | − | Vaccine immune — protected |
| − | + | + | − | − | Past infection, now immune |
| + | − | + | + | Variable | Acute HBV infection |
| + | − | + | − | + | Chronic HBV — high replication |
| + | − | + | − | − | Chronic HBV — low replication/carrier |
| − | − | + | − | − | Isolated anti-HBc — occult HBV / window period / false positive |
HBV Treatment
First-line Antivirals (oral, indefinite in most)
- Tenofovir disoproxil fumarate (TDF) — high barrier to resistance; preferred in adults
- Tenofovir alafenamide (TAF) — improved renal/bone safety profile
- Entecavir — high barrier; preferred in renal impairment
Pegylated Interferon alfa-2a
- 48-week course (finite duration)
- Suitable for young patients, HBeAg-positive, high ALT
- Contraindicated in decompensated cirrhosis
Treatment Endpoints
- HBeAg seroconversion (HBeAg− / anti-HBe+)
- Undetectable HBV DNA
- HBsAg loss — "functional cure" (rare but ideal)
- ALT normalisation
HBV Reactivation
High Risk: Immunosuppressive therapy (rituximab, chemotherapy, biologics, steroids, post-transplant)
Screening Before Immunosuppression
- Check HBsAg AND anti-HBc in ALL patients before:
- Chemotherapy, biologic therapy (anti-TNF, anti-CD20)
- High-dose steroids (>20mg/day >4 weeks)
- Organ transplantation
Prophylactic Antiviral Strategy
- HBsAg+ → Start antiviral (tenofovir/entecavir) BEFORE immunosuppression; continue for 6–12 months after
- Isolated anti-HBc+ → Monitor HBV DNA monthly OR prophylactic antiviral if high-risk regimen
- Monitor LFTs regularly throughout immunosuppression
HBV Vaccination Programme — GCC
Standard 3-Dose Schedule
- Dose 1: Birth (within 12–24 hours)
- Dose 2: 1 month of age
- Dose 3: 6 months of age
- Anti-HBs >10 IU/L = protective
Perinatal Prevention
- All mothers screened for HBsAg antenatally
- HBeAg-positive mothers: Infant receives HBIG + vaccine within 12 hours of birth
- Tenofovir in 3rd trimester if HBV DNA >200,000 IU/mL
Healthcare Workers
- Mandatory vaccination in all GCC countries
- Anti-HBs titre check post-vaccination
- Non-responders: Repeat 3-dose course
- If still non-responder: Counsel on HBV risk; HBIG if exposed
HCC Surveillance
Indication: All patients with cirrhosis; HBV patients without cirrhosis if age >40 (especially Asian males) or family history of HCC.
- Ultrasound abdomen every 6 months
- Serum AFP every 6 months (adjunct — not standalone)
- CT/MRI if USS shows suspicious lesion >1 cm (LIRADS criteria)
- GCC: High burden of HBV-related HCC — surveillance is a nursing priority
Hepatitis C — Diagnosis, Treatment & GCC Elimination
Transmission & Epidemiology
RNA Flavivirus
Blood-Borne
- Intravenous drug use (IVDU) — most common in developed countries
- Blood transfusion before 1992 (pre-screening era)
- Healthcare-associated — unsafe injection practices, reuse of equipment
- Sexual transmission — low risk; higher with multiple partners
- Vertical transmission — 5% (lower than HBV)
GCC Context: Egypt has the highest HCV prevalence globally (~10% historically), largely due to mass parenteral antischistosomal therapy campaigns. Egyptian expat workers in GCC represent a significant at-risk population.
Natural History
- ~20–25% clear spontaneously
- ~75–80% develop chronic infection
- 20–30% of chronic HCV progress to cirrhosis over 20–30 years
- HCC develops in 1–5% per year in cirrhotic patients
Diagnosis Pathway
Step 1 — Screening
Anti-HCV antibody (ELISA) — detects past or current exposure. Positive from 8–12 weeks post-infection.
Step 2 — Confirmation
HCV RNA (PCR) — confirms active viraemia. Detectable within 1–2 weeks of infection. Negative HCV RNA with positive anti-HCV = past cleared infection.
Step 3 — Genotyping
HCV Genotype (GT1–6) — guides treatment selection. GT1 most common globally; GT4 prevalent in Egypt/Middle East; GT3 in South Asia.
Step 4 — Staging
Liver fibrosis assessment: FIB-4 index / Fibroscan / liver biopsy. Staging guides urgency and duration of treatment.
Direct-Acting Antivirals (DAAs) — Hepatitis C Treatment
DAAs achieve >95% SVR (Sustained Virological Response = cure) across all genotypes with 8–12 weeks of oral therapy. Pan-genotypic regimens now allow treatment without genotyping.
Common DAA Regimens
| Regimen | Genotype | Duration | Key Notes |
|---|
| Sofosbuvir/Ledipasvir | GT1, GT4, GT5, GT6 | 8–12 wks | 8 wks if treatment-naive, no cirrhosis |
| Sofosbuvir/Daclatasvir | Pan-genotypic | 12 wks | Available in many GCC national programmes |
| Glecaprevir/Pibrentasvir (Mavyret) | Pan-genotypic | 8–12 wks | 8 wks for treatment-naive without cirrhosis |
| Sofosbuvir/Velpatasvir (Epclusa) | Pan-genotypic | 12 wks | First-line in many guidelines |
Treatment Monitoring Schedule
Baseline
HCV RNA quantitative, LFTs, renal function, FBC, genotype, fibrosis staging, pregnancy test
Week 4 (RVR)
HCV RNA — rapid virological response. If detectable, assess adherence
End of Treatment (EOT)
HCV RNA — should be undetectable
Week 12 Post-EOT (SVR12)
SVR12 = CURE. HCV RNA undetectable 12 weeks after completing treatment
Post-SVR (cirrhosis)
Continue 6-monthly HCC surveillance even after cure if cirrhosis present
Cirrhosis Decompensation Management
Signs of Decompensation
- Ascites (treat with spironolactone ± furosemide, low-sodium diet)
- Variceal haemorrhage (urgent endoscopy, octreotide, terlipressin)
- Spontaneous bacterial peritonitis (SBP) — diagnostic paracentesis
- Hepatic encephalopathy (lactulose, rifaximin)
- Hepatorenal syndrome — specialist input required
Decompensated cirrhosis patients being treated with DAAs — use sofosbuvir-based regimens; NS3/4A protease inhibitors (glecaprevir/grazoprevir) are CONTRAINDICATED in Child-Pugh B/C cirrhosis.
GCC HCV Elimination Targets
WHO targets 2030: 90% reduction in new infections, 65% reduction in mortality, 80% treatment coverage.
- UAE: National HCV elimination programme underway; DHA-led treatment programmes
- Saudi Arabia: National hepatitis strategy; free DAA treatment in MOH facilities
- Qatar: Universal screening for high-risk groups (QCHP initiative)
- Egypt expat screening: Critical component of GCC elimination — GT4 predominant
- Nursing role: Case identification, treatment adherence support, SVR monitoring
Pre-Treatment Checklist
- Confirm HCV RNA positive (active infection)
- Document HCV genotype (if pan-genotypic regimen not used)
- Liver fibrosis stage (FIB-4, Fibroscan)
- Baseline LFTs, renal function (eGFR), FBC, bilirubin, INR
- Hepatitis B co-infection screen (HBsAg — risk of HBV reactivation during DAA therapy)
- HIV status
- Pregnancy test in women of childbearing age; contraception counselling
- Drug interaction review (PPIs, amiodarone, rifampicin — significant interactions)
- Alcohol and drug use counselling
- Reinfection risk reduction counselling (needle exchange, harm reduction)
During Treatment
- Adherence assessment at each visit — DAAs require strict daily dosing
- Week 4 HCV RNA (RVR check)
- Side-effect monitoring: fatigue, headache, nausea (mild with modern DAAs)
- Amiodarone + sofosbuvir: Bradycardia risk — cardiac monitoring required
- Monitor for HBV reactivation if HBsAg+ or isolated anti-HBc+
Post-Treatment
- SVR12 HCV RNA test (12 weeks post-end of treatment)
- Repeat LFTs and FBC at SVR12
- If cirrhosis: Continue 6-monthly USS + AFP surveillance
- Counsel: Reinfection is possible — SVR is not immunity
- Document SVR12 result in patient records and notify referring clinician
Nursing Care & Complication Management
Acute Hepatitis Nursing Care
Rest & Activity
- Bed rest during acute phase (fatigue is profound)
- Gradual mobilisation as jaundice and symptoms improve
- No specific activity restriction once recovering
Nutrition
- High-carbohydrate, low-fat diet during acute phase
- Small frequent meals (nausea management)
- IV fluids if oral intake inadequate
- Avoid alcohol absolutely
- Adequate caloric intake critical — malnutrition worsens prognosis
Drug Review — Hepatotoxicity Risk
- Review ALL medications for hepatotoxicity
- Paracetamol: Reduce dose to max 2g/day (avoid entirely if severe disease)
- Avoid: NSAIDs (renal risk in cirrhosis), statins (generally safe to continue), rifampicin
- Review herbal supplements — many are hepatotoxic
- Check opioid doses (reduced hepatic metabolism)
Jaundice Management
Monitoring
- Serial serum bilirubin (total + direct/indirect)
- LFTs trend: ALT, AST, ALP, GGT
- Observe urine colour (dark = conjugated bilirubinuria)
- Stool colour (pale/clay = biliary obstruction)
Pruritus Management
- First line: Cholestyramine 4g twice daily (bile acid sequestrant)
- Second line: Antihistamines (sedating — chlorphenamine)
- Third line: Ursodeoxycholic acid (UDCA) — especially cholestatic disease
- Rifampicin 150–300mg daily (cholestatic pruritus — specialist prescription)
Skin Care
- Tepid baths — avoid hot water (worsens pruritus)
- Emollient creams (unscented)
- Loose cotton clothing
- Keep fingernails short (prevent excoriation)
- Assess for skin breakdown and secondary infection
Coagulopathy Monitoring
The liver synthesises clotting factors (I, II, V, VII, IX, X). Hepatic failure impairs coagulation — INR rises are an early warning sign.
Monitoring
- INR (prothrombin time) — most sensitive marker of synthetic function
- Platelet count (thrombocytopenia in portal hypertension)
- Fibrinogen level
Nursing Actions
- Avoid IM injections when INR >1.5 — risk of haematoma
- Avoid invasive procedures without correction of INR
- Vitamin K IV (phytomenadione 10mg IV) — if INR elevated (assess response)
- Fresh Frozen Plasma (FFP) if active bleeding or pre-procedure
- Apply pressure to all venepuncture sites for at least 5 minutes
- Use smallest gauge needle possible
- Monitor for signs of bleeding: haematuria, melaena, ecchymosis
Hepatic Encephalopathy (HE)
Early Recognition
| Grade | Signs |
|---|
| Grade 1 | Subtle personality change, sleep reversal, mild confusion |
| Grade 2 | Lethargy, disorientation, asterixis (flapping tremor) |
| Grade 3 | Marked confusion, somnolence, incomprehensible speech |
| Grade 4 | Coma — unresponsive to stimuli |
Assessment
- Asterixis: Ask patient to extend arms, dorsiflex wrists — flapping = positive
- Serum ammonia level (elevated >50 μmol/L)
- GCS monitoring
- Identify precipitating cause: infection (SBP), GI bleed, constipation, diuretics
Management
- Lactulose 15–30ml TDS–QDS (titrate to 2–3 soft stools/day)
- Rifaximin 550mg BD (prevention of recurrence)
- Treat precipitant; ensure adequate nutrition (do not restrict protein)
- Airway protection in grade 3–4 (consider ICU)
Acute Liver Failure (ALF) — Recognition & Escalation
Definition: Jaundice + coagulopathy (INR >1.5) + encephalopathy within 26 weeks of illness onset in previously healthy liver.
Alarm Features — Escalate Immediately
- INR >2.0 and rising
- Bilirubin >300 μmol/L (or doubling in 24h)
- Any degree of encephalopathy
- Hypoglycaemia (monitor glucose hourly in severe ALF)
- Renal dysfunction (hepatorenal syndrome)
- Haemodynamic instability
King's College Criteria (Transplant Listing)
Indicates need for urgent liver transplant assessment:
Paracetamol ALF: pH <7.30 OR (INR >6.5 + creatinine >300 + grade 3–4 HE)
Non-paracetamol ALF: INR >6.5 OR any 3 of: unfavourable aetiology, age <10 or >40, jaundice >7 days before HE, INR >3.5, bilirubin >300
Contact transplant centre early — referral should not be delayed
Standard Precautions — Blood-Borne Virus Hepatitis
- Treat ALL blood and body fluids as potentially infectious (standard/universal precautions)
- Gloves for all blood/body fluid contact; double-glove for high-risk procedures
- Eye protection and apron when splash risk present
- Safe disposal of sharps immediately after use — no re-sheathing of needles
- Safety-engineered devices where available
- Hepatitis B vaccination mandatory for all GCC healthcare workers
- Private room not required for HBV/HCV — not airborne
- No restriction on sharing crockery or general equipment
Infection Control & Occupational Exposure Management
Blood-Borne Virus Transmission Risk
HBV
6–30%
Per needlestick injury from HBeAg+ source
Highest risk BBV
HCV
1.8%
Per needlestick from HCV RNA+ source
Intermediate risk
HIV
0.3%
Per needlestick from HIV+ source
Lower risk but serious
TIME IS CRITICAL — Act within minutes, not hours
Immediate (0–5 minutes)
1. Wash the wound thoroughly with soap and water for at least 2 minutes
2. Allow to bleed freely under running water — do NOT suck the wound
3. Cover with waterproof dressing
4. Stop working — delegate patient care
Within 1–2 Hours
5. Report to line manager / Occupational Health (OH) / Emergency Department
6. Source patient assessment: HBsAg, anti-HCV, HIV status (with consent)
7. Exposed person assessment: HBV vaccination history, anti-HBs titre
8. HBV HBIG: If non-immune (anti-HBs <10 IU/L) — administer HBIG within 24 hours (ideally <12h) + accelerated HBV vaccine course
9. HIV PEP assessment: Initiate if source HIV+ or unknown high-risk — must start within 72 hours (preferably <4h)
Within 24 Hours
10. Baseline blood tests on exposed HCW: HBsAg, anti-HCV, HIV Ag/Ab, LFTs
11. Complete incident form (mandatory reporting in all GCC facilities)
12. Counselling: Safer sex, avoid blood donation until cleared
HCV Follow-Up (6 weeks & 6 months)
HCV RNA at 6 weeks (early detection — allows early treatment)
Anti-HCV at 6 months — confirms seroconversion or clearance
If HCV RNA positive at 6 weeks → refer to hepatologist; DAA treatment highly effective
HIV Follow-Up
HIV Ag/Ab at 4–6 weeks, 3 months if on PEP, 6 months (if PEP not taken)
Complete PEP course (28 days) if started
Adherence support — nausea common with PEP
HBIG Indications
- Non-immune HCW (anti-HBs <10 IU/L) exposed to HBsAg+ source
- Give within 24 hours (ideally <12h) — efficacy declines after 24h
- 400 IU IM (deltoid) as single dose
- Also start or complete HBV vaccine course
HIV PEP Regimen
- Start within 72 hours (sooner = better)
- Standard regimen: Tenofovir/emtricitabine + raltegravir (or dolutegravir)
- 28-day course
- GCC facilities should have PEP starter packs in ED
| Pattern | HBsAg | Anti-HBs | Anti-HBc | IgM Anti-HBc | HBeAg | HBV DNA | Interpretation & Action |
|---|
| Susceptible | − | − | − | − | − | − | Never infected, not vaccinated → Vaccinate |
| Vaccine immune | − | + | − | − | − | − | Protected by vaccination → No action |
| Natural immunity | − | + | + | − | − | − | Past infection, cleared → No action |
| Acute HBV | + | − | + | + | +/− | High | Acute infection → Notify, support, monitor |
| Chronic HBV HiRep | + | − | + | − | + | High | Chronic, high replication → Treat (TDF/ETV) |
| Chronic HBV LoRep | + | − | + | − | − | Low | Inactive carrier → Monitor LFTs/HBV DNA 6-monthly |
| Occult/Window | − | − | + | − | − | Low/− | Isolated anti-HBc: Check HBV DNA; occult HBV/window/false+ |
Window Period: During early acute infection, HBsAg may be cleared before anti-HBs appears. IgM anti-HBc is the only positive marker — do not miss this.
Universal Precautions — Key Principles
Always Required
- Hand hygiene before and after all patient contact
- Gloves for blood, body fluids, non-intact skin, mucous membranes
- Gown/apron for procedures with splash risk
- Eye/face protection when aerosol or splash risk
- Safe sharps disposal — single-handed technique or safety devices
- Never recap needles using two hands
GCC Regulatory Requirements
- HBV vaccination mandatory for all GCC HCWs (DHA/MOH/HAAD/QCHP)
- Anti-HBs titre documentation required for clinical placement
- Annual blood-borne virus competency assessment in most facilities
- Sharps injury reporting mandatory — all GCC health authority guidelines
- Occupational health programmes must include BBV counselling and testing
GCC Context, Exam Prep & Cultural Considerations
Viral Hepatitis Prevalence in GCC
| Country/Group | HBsAg Prevalence | Anti-HCV Prevalence | Key Notes |
|---|
| Saudi Arabia | 1–3% | <1% | Mandatory neonatal HBV vaccination since 1989 |
| UAE | <1% (nationals) | <1% | Post-vaccination era; DHA elimination programme |
| Qatar | ~1–2% | <1% | QCHP HCV screening programme |
| Kuwait/Oman/Bahrain | 1–2% | <1% | Regional vaccination successes |
| Egyptian expat workers | 2–4% | ~5–10% (historical) | Highest HCV risk group in GCC; GT4 predominant |
| South Asian expat workers | 2–5% | Variable | Higher HBV carriage; HEV risk from endemic regions |
Vertical Transmission Prevention — GCC Protocols
Target: <1% mother-to-child transmission rate — achievable with proper protocols
Antenatal
- Universal HBsAg screening for ALL pregnant women (GCC standard)
- HBeAg and HBV DNA quantification if HBsAg+
- If HBV DNA >200,000 IU/mL → Tenofovir from 28–32 weeks gestation
Birth (within 12 hours — CRITICAL TIMING)
- HBV vaccine dose 1 (birth dose) to all infants of HBsAg+ mothers
- If mother HBeAg+ or HBV DNA >200,000: Add HBIG 200 IU IM within 12 hours of birth
- Complete 3-dose vaccine schedule (birth, 1 month, 6 months)
Postnatal
- Breastfeeding is SAFE — HBV vaccination does not preclude breastfeeding
- Infant serology at 9–12 months: HBsAg + anti-HBs
- If infant HBsAg+ → Refer to paediatric hepatology
Ramadan & Fasting — Hepatitis Management
HBV Treatment During Ramadan
- Tenofovir and Entecavir: Once-daily dosing — can be taken at Iftar (break-fast meal)
- Entecavir specifically should be taken on an empty stomach — 2 hours before/after food. Take at Suhoor (pre-dawn meal) or at Iftar timing but adjust food intake
- No dose interruptions — adherence is critical to prevent resistance
- Remind patients not to skip doses during Ramadan
HCV DAA Treatment During Ramadan
- DAAs are generally taken with food — Iftar timing is suitable
- Sofosbuvir/ledipasvir and sofosbuvir/velpatasvir: Can be taken with Iftar or Suhoor
- Glecaprevir/pibrentasvir: Take with food (Iftar meal)
- Dehydration risk — encourage adequate fluid intake in non-fasting hours
- Consider scheduling treatment initiation outside Ramadan for complex cases
Nursing role: Assess fasting intentions at each consultation; provide culturally sensitive medication timing guidance. Document religious accommodation in care plan.
GCC Regulatory & Nursing Competencies
DHA (Dubai Health Authority)
- DHA hepatology nursing competency framework includes viral hepatitis management
- DHA licensing exam: HBV serology interpretation is a recurring topic
- Infection control certification mandatory for all DHA-licensed nurses
DOH (Department of Health — Abu Dhabi)
- HAAD/DOH nurse exam includes hepatitis B vaccination policy
- Occupational health exposure management competency required
SCFHS (Saudi Commission for Health Specialties)
- Saudi Prometric exam: Hepatitis B serology, infection control, HCC surveillance
- Hepatology nursing sub-specialty content
QCHP (Qatar Council for Healthcare Practitioners)
- Qatar Prometric: BBV transmission, needlestick management, HCV treatment
- National HCV elimination programme awareness required
Islamic Perspective — Liver Transplant & Organ Donation
Liver transplantation is the definitive treatment for end-stage liver disease from HBV/HCV cirrhosis and ALF. Islamic jurisprudence has addressed organ donation:
- Majority Islamic scholar position: Organ donation is permissible (جائز) — saving a life takes precedence (إحياء النفس)
- Islamic Fiqh Academy (OIC) Resolution 1988: Organ donation permitted after brain-stem death
- GCC National fatwa councils in Saudi Arabia, UAE, Qatar, Kuwait have issued permissibility rulings for deceased donor transplantation
- Living donor liver transplant (LDLT): Highly practised in Saudi Arabia (King Faisal Specialist Hospital) and UAE — donating a portion of the liver is permitted
- Nursing role: Provide accurate information; involve religious/pastoral support; respect family's spiritual concerns; do not impose views
- Alcohol-related liver disease may raise ethical questions — non-judgmental care required
GCC Exam Prep — MCQs (DHA/MOH/SCFHS/QCHP Style)
1. A 28-year-old pregnant woman (32 weeks gestation) presents with jaundice, elevated LFTs, and is found to be anti-HEV IgM positive. What is the MOST appropriate immediate management?
- A. Reassure and discharge with oral hydration
- B. Prescribe ribavirin and monitor as outpatient
- C. Admit to hospital for close monitoring
- D. Start tenofovir immediately
- E. Perform liver biopsy to confirm severity
Answer: C — HEV in pregnancy (especially 3rd trimester) carries up to 25% maternal mortality from fulminant hepatic failure. Hospital admission is MANDATORY. Ribavirin is teratogenic and NOT used in pregnancy. Tenofovir is for HBV, not HEV.
2. A healthcare worker sustains a needlestick injury from a patient with known chronic hepatitis B. The HCW's anti-HBs titre is 5 IU/L. What is the PRIORITY intervention within 24 hours?
- A. Start tenofovir prophylaxis immediately
- B. Monitor LFTs every 2 weeks — no immediate action needed
- C. Administer HIV post-exposure prophylaxis
- D. Administer HBIG and commence accelerated HBV vaccination course
- E. Repeat anti-HBs titre in 6 months
Answer: D — Anti-HBs <10 IU/L = non-immune. HBIG should be given within 24 hours (ideally <12h) along with an accelerated HBV vaccine course. Tenofovir is not used for post-exposure prophylaxis against HBV.
3. A 45-year-old Egyptian male expat worker in Dubai is found to have: HBsAg negative, anti-HCV positive, HCV RNA 2.5 million IU/mL, HCV genotype 4. Which DAA regimen is MOST appropriate for a treatment-naive patient without cirrhosis?
- A. Pegylated interferon + ribavirin for 48 weeks
- B. Sofosbuvir/ledipasvir for 12 weeks (approved for GT1, GT4, GT5, GT6)
- C. Entecavir monotherapy for 24 weeks
- D. Sofosbuvir/velpatasvir (pan-genotypic) for 12 weeks
- E. No treatment — GT4 HCV has no licensed therapy in GCC
Answer: D (also B is acceptable) — Sofosbuvir/velpatasvir is pan-genotypic and highly effective for GT4. Sofosbuvir/ledipasvir is also licensed for GT4 (12 weeks). SVR rates >95%. Pan-genotypic regimens are preferred in GCC given GT4 prevalence in Egyptian expat workers. Interferon-based regimens are now obsolete. Entecavir is for HBV only.
4. A nurse assesses a patient with known chronic HBV cirrhosis who appears confused and has difficulty performing simple tasks. On examination, bilateral flapping tremor (asterixis) is noted. Serum ammonia is 85 μmol/L. Which medication is the FIRST-LINE treatment?
- A. Rifaximin 550mg BD
- B. Neomycin enema
- C. Lactulose 15–30ml three to four times daily (titrated to 2–3 stools/day)
- D. Metronidazole 400mg TDS
- E. Protein-restricted diet immediately
Answer: C — Lactulose is first-line for hepatic encephalopathy. It reduces ammonia absorption by acidifying the colon, trapping ammonia as ammonium. Rifaximin is used as secondary prophylaxis or adjunct. Protein restriction is NOT recommended — adequate nutrition is important. Neomycin is rarely used due to ototoxicity/nephrotoxicity.
5. A patient's hepatitis B serology results show: HBsAg negative, anti-HBs negative, anti-HBc total positive, IgM anti-HBc negative, HBeAg negative. HBV DNA is <10 IU/mL. What is the MOST likely interpretation?
- A. Acute hepatitis B infection
- B. Chronic hepatitis B with low replication
- C. Successfully vaccinated individual
- D. Isolated anti-HBc — occult HBV, window period, or false positive
- E. Immune due to previous vaccination
Answer: D — Isolated anti-HBc (HBsAg−, anti-HBs−, anti-HBc+ only) represents three possible scenarios: (1) Window period of acute HBV — check IgM anti-HBc; (2) Occult HBV infection — low-level replication below assay detection; (3) False positive anti-HBc. Clinical context and HBV DNA testing help differentiate. This patient requires prophylactic antiviral before immunosuppression. Vaccine immunity produces anti-HBs ONLY (no anti-HBc).